US 12,473,347 B2
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
Hans G. Klingemann, Culver City, CA (US); Laurent H. Boissel, Culver City, CA (US); and Abhijit Dandapat, Culver City, CA (US)
Assigned to ImmunityBio, Inc., San Diego, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Jun. 23, 2021, as Appl. No. 17/356,411.
Application 17/356,411 is a division of application No. 16/529,159, filed on Aug. 1, 2019, granted, now 11,077,143.
Claims priority of provisional application 62/753,740, filed on Oct. 31, 2018.
Prior Publication US 2021/0322477 A1, Oct. 21, 2021
Int. Cl. C07K 14/735 (2006.01); A61K 40/15 (2025.01); A61K 40/30 (2025.01); A61K 40/31 (2025.01); A61K 40/35 (2025.01); A61K 40/42 (2025.01); A61P 35/04 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 14/70535 (2013.01) [A61K 40/15 (2025.01); A61K 40/30 (2025.01); A61K 40/31 (2025.01); A61K 40/35 (2025.01); A61K 40/4224 (2025.01); A61P 35/04 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/7051 (2013.01); C07K 16/2827 (2013.01); C12N 5/0646 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for killing a programmed death-ligand 1 (PD-L1) expressing cell, the method comprising:
contacting the PD-L1 expressing cell with a plurality of recombinant NK-92 cells that each express an anti-PD-L1 chimeric antigen receptor (CAR) and an Fc receptor,
wherein the PD-L1 expressing cell is a myeloid-derived suppressor cell (MDSC) or a tumor associated macrophage (TAM),
wherein the CAR has at least 90% sequence identity to SEQ ID NO: 15.